Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages - Gomez-Roca, C A; Italiano, A; Le Tourneau, C (Ann Oncol, 2019)